Bristol-Myers Squibb researches, develops, and sells prescription medicines focused on oncology, hematology, immunology, and cardiovascular conditions. Its portfolio includes biologic therapies and small-molecule drugs that address specific disease mechanisms, often in areas with high unmet need. The company commercializes these products through healthcare providers and payers worldwide.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 12,269 | — | 1,310 | — |
| Q3 2025 | 12,222 | — | 2,201 | — |
| Q4 2025 | 12,503 | — | 1,087 | — |
| Q1 2026 | 11,489 | — | 2,677 | — |
| Q2 2026 | 12,973 | 5.7% | 3,317 | 153.2% |
All markets — KeepWinning global stock screener
Other companies on NYSE: Parker-Hannifin Corporation (PH), Medtronic plc (MDT), CVS Health Corporation (CVS), McKesson Corporation (MCK), Phillips 66 (PSX), Bank of Montreal (BMO)